Category: psoriasis

A real-world study of psoriasis (PsO) and psoriatic arthritis (PsA) patients with apremilast reported no new adverse events or safety signals with results comparable to previous clinical trials.

A new real-world study showed IL-23 inhibitors to be highly effective for the treatment of chronic plaque psoriasis in both biologic-naïve and biologic-non-naïve patients. 

According to a new study, patients with psoriasis have a 20% greater risk of organ-based comorbidities when compared with the general population.

Patients with psoriasis value skin clearance and symptom control as the most important treatment outcomes, according to a new study.

According to a new study, tildrakizumab treatment for psoriasis showed a significant improvement when used for difficult-to-treat areas such as the scalp, nail, palms and genitals.

According to a new study, patients with psoriasis are at an increased risk of developing alopecia areata. 

According to a new study, psoriasis patients, with and without psoriatic arthritis (PsA), self-report using analgesics more than those without the disease. This may be due to increased joint pain.

A new study has shown that clinical response in psoriasis patients treated with ustekinumab tends to vary by anatomical region, with the lower extremities seeing the least response.

Findings from a new study has shown that early response to ixekizumab and ustekinumab is associated with maintaining stable long-term skin clearance in patients with moderate-to-severe psoriasis.

According to a new study, some psoriasis patients may experience a reduction in shame and improvement in quality of life (QOL) after exposure to self-help interventions.